Published in Vaccine Weekly, October 8th, 2003
InNexus' SAT technology can increase the binding strength of monoclonal antibodies, which allows them to cross-link their target antigen. This process can trigger "apoptosis," or cell suicide, or the enhancement of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.